{"id":744904,"date":"2014-11-03T05:00:00","date_gmt":"2014-11-03T05:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/"},"modified":"2023-03-22T00:04:49","modified_gmt":"2023-03-22T04:04:49","slug":"merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/","title":{"rendered":"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients"},"content":{"rendered":"<p class=\"bwalignc\">       Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of        2014     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of results from a Phase 2b clinical<br \/>\n      trial evaluating the safety and efficacy of once-daily oral doravirine,<br \/>\n      an investigational next-generation non-nucleoside reverse transcriptase<br \/>\n      inhibitor (NNRTI), plus tenofovir\/emtricitabine (TDF\/FTC) compared to<br \/>\n      efavirenz plus TDF\/FTC in previously untreated patients with HIV-1<br \/>\n      infection. Results were presented as a poster (#0434) and oral<br \/>\n      presentation by Dr. Josep M. Gatell, head, Infectious Diseases and AIDS<br \/>\n      Units-IDIBAPS, Hospital Clinic, Barcelona, at the 12<sup>th<\/sup><br \/>\n      International Congress on HIV Drug Therapy being held in Glasgow, United<br \/>\n      Kingdom, Nov. 2-6.\n    <\/p>\n<p>\n      The primary safety analysis from the expansion phase of the study<br \/>\n      compared the incidence of central nervous system (CNS) adverse events<br \/>\n      (AEs) by Week 8 in patients who received doravirine 100 mg plus TDF\/FTC<br \/>\n      (n=108) versus patients who received efavirenz with TDF\/FTC (n=108). The<br \/>\n      results showed a significantly lower incidence of one or more of<br \/>\n      reported CNS AEs (all causality) among the doravirine-treated group<br \/>\n      compared to the efavirenz-treated group (22.2 % vs. 43.5 %,<br \/>\n      respectively; p&lt;0.001). The most common (occurring in more than 5<br \/>\n      percent of patients) CNS AEs in the doravirine-and efavirenz-treated<br \/>\n      groups, respectively, were dizziness (9.3 % vs. 27.8 %), insomnia (6.5 %<br \/>\n      vs. 2.8 %), abnormal dreams (5.6 % vs. 16.7 %) and nightmares (5.6 % vs.<br \/>\n      8.3 %).\n    <\/p>\n<p>\n      Interim results for this ongoing Phase 2b study, including the primary<br \/>\n      efficacy analysis for dose selection based on 24-week data from the<br \/>\n      dose-ranging cohort of the study, were previously presented at the 21<sup>st<\/sup>&nbsp;Conference<br \/>\n      on Retroviruses and Opportunistic Infections (CROI) in <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fresearch-and-development-news%2Fmercks-investigational-hiv-therapy-doravirine-mk-1439-dem&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=March+2014&amp;index=1&amp;md5=9e80840a5a62245a6bc0a17223e3099d\" rel=\"nofollow\">March<br \/>\n      2014<\/a>.\n    <\/p>\n<p>\n      \u201cThis program underscores Merck\u2019s ongoing commitment to the research and<br \/>\n      development of new therapeutic options for patients with HIV,\u201d said Dr.<br \/>\n      Hedy Teppler, executive director, Infectious Diseases, Merck Research<br \/>\n      Laboratories. \u201cWe are encouraged by the antiviral activity and the<br \/>\n      overall tolerability profile of doravirine and look forward to<br \/>\n      initiating Phase 3 studies.\u201d\n    <\/p>\n<p>\n      Additional follow-up data through 48 weeks of treatment showed a 76<br \/>\n      percent (n=126\/166) overall virologic response rate (HIV RNA &lt;40 c\/ml)<br \/>\n      for all doravirine doses (25, 50, 100 and 200 mg) that is comparable to<br \/>\n      71 percent (n=30\/42) reported for patients administered efavirenz (600<br \/>\n      mg). In addition, all treatment groups showed increased CD4 cell counts<br \/>\n      relative to baseline, consistent with the 24-week findings.\n    <\/p>\n<p>\n      After 48 weeks of treatment, patients in the dose ranging part of the<br \/>\n      study who received doravirine demonstrated a lower overall incidence of<br \/>\n      drug-related adverse events (36.7%; n=166) than those who received<br \/>\n      efavirenz (57.1%; n=42). The most commonly reported drug-related<br \/>\n      clinical adverse events in the doravirine and efavirenz groups<br \/>\n      respectively were abnormal dreams (10.2% vs. 9.5%); nausea (7.8% vs.<br \/>\n      2.4%); fatigue (7.2% vs. 4.8%); diarrhea (4.8% vs. 9.5%) and dizziness<br \/>\n      (3.0% vs. 23.8%). Doravirine-treated patients also had a lower incidence<br \/>\n      of laboratory abnormalities in routine clinical tests including<br \/>\n      increased total cholesterol (6.8% for doravirine vs. 31.6% for<br \/>\n      efavirenz) and LDL cholesterol (6.3% for doravirine vs. 18.4% for<br \/>\n      efavirenz).\n    <\/p>\n<p>\n      Merck plans to initiate the first Phase 3 clinical trial of doravirine<br \/>\n      by the end of 2014, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02275780%3Fterm%3DNCT02275780%26rank%3D1&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=NCT02275780&amp;index=2&amp;md5=6095475edf624e32152346f1202c1515\" rel=\"nofollow\">NCT02275780<\/a>.<br \/>\n      The study will enroll treatment-na\u00efve patients and compare the efficacy,<br \/>\n      safety and tolerability of doravirine and ritonavir-boosted darunavir,<br \/>\n      both in combination with other anti-retroviral therapy.\n    <\/p>\n<p>\n      <b>About the Phase 2b Study<\/b>\n    <\/p>\n<p>\n      The Phase 2b randomized, double blind, dose-ranging clinical trial (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Fsearch.html%3Fkw%3DNCT01632345&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=NCT01632345&amp;index=3&amp;md5=dce1433303eb2a2428f21b89e3b02c0b\" rel=\"nofollow\">NCT01632345<\/a>)<br \/>\n      evaluated the efficacy, safety and tolerability of once-daily doravirine<br \/>\n      (25, 50, 100 and 200 mg) compared to once-daily efavirenz 600 mg, both<br \/>\n      in combination with TDF\/FTC, in previously untreated HIV-1 infected<br \/>\n      patients. The study has two parts:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In Part 1, the dose-ranging phase, patients received once daily<br \/>\n        doravirine (N=166) at one of four doses (25, 50, 100 or 200 mg) or<br \/>\n        efavirenz (n=42), both in combination with TDF\/FTC. The doravirine<br \/>\n        dose to be used in Part 2 of the Phase 2b study and in Phase 3 was<br \/>\n        selected based on the Week 24 safety and efficacy data in<br \/>\n        doravirine-treated patients. After dose selection, all<br \/>\n        doravirine-treated patients were switched to the selected dose (100 mg<br \/>\n        doravirine) for the expansion phase of the study.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In Part 2, the expansion phase, an additional 132 patients were<br \/>\n        enrolled to receive 100 mg doravirine (n=66) or efavirenz (n=66), both<br \/>\n        in combination with TDF\/FTC, to enable an assessment of the CNS safety<br \/>\n        and tolerability profile of doravirine.\n      <\/li>\n<\/ul>\n<p>\n      The planned total treatment duration in the Phase 2 study is 96 weeks.\n    <\/p>\n<p>\n      <b>About Doravirine<\/b>\n    <\/p>\n<p>\n      Doravirine, also known as MK-1439, is an investigational<br \/>\n      next-generation, NNRTI being developed by Merck for the treatment of<br \/>\n      HIV-1 infection. In preclinical studies, doravirine showed potent<br \/>\n      antiviral activity against HIV-1. In early clinical studies, doravirine<br \/>\n      demonstrated a pharmacokinetic profile supportive of a once-daily dosing<br \/>\n      schedule and did not show a significant food effect.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HIV<\/b>\n    <\/p>\n<p>\n      For more than 25 years, Merck has been at the forefront of the response<br \/>\n      to the HIV epidemic, and has helped to make a difference through our<br \/>\n      proud legacy of commitment to innovation, collaboration with the<br \/>\n      community, and expanding global access to medicines. Merck is dedicated<br \/>\n      to applying our scientific expertise, resources and global reach to<br \/>\n      deliver healthcare solutions that support people living with HIV<br \/>\n      worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=f844168d735265f097746abc20fcd004\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=70df8357ebf1d607476c6590eedc675f\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=c06eebe7f80678c3da20bbd5f3ff211d\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=992cc30c0042dd13dc631c1ec3a27468\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50974405&amp;newsitemid=20141103005159&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=18d50f324651f23b629d299d61cd7377\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Carmen        de Gourville, 267-664-0146<br \/>or<br \/>Investors:<br \/>Joseph        Romanelli, 908-423-5185<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir\/emtricitabine (TDF\/FTC) compared to efavirenz plus TDF\/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Josep M. Gatell, head, Infectious Diseases and AIDS Units-IDIBAPS, Hospital Clinic, Barcelona, at the 12th International Congress on HIV Drug Therapy being held in Glasgow, United Kingdom, Nov. 2-6. The primary safety analysis from the expansion phase of the study compared the incidence of central nervous system (CNS) adverse events (AEs) by Week 8 in patients who received doravirine 100 mg plus TDF\/FTC (n=108) versus<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-744904","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir\/emtricitabine (TDF\/FTC) compared to efavirenz plus TDF\/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Josep M. Gatell, head, Infectious Diseases and AIDS Units-IDIBAPS, Hospital Clinic, Barcelona, at the 12th International Congress on HIV Drug Therapy being held in Glasgow, United Kingdom, Nov. 2-6. The primary safety analysis from the expansion phase of the study compared the incidence of central nervous system (CNS) adverse events (AEs) by Week 8 in patients who received doravirine 100 mg plus TDF\/FTC (n=108) versus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:49+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/\",\"name\":\"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-11-03T05:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - Merck.com","og_description":"Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir\/emtricitabine (TDF\/FTC) compared to efavirenz plus TDF\/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Josep M. Gatell, head, Infectious Diseases and AIDS Units-IDIBAPS, Hospital Clinic, Barcelona, at the 12th International Congress on HIV Drug Therapy being held in Glasgow, United Kingdom, Nov. 2-6. The primary safety analysis from the expansion phase of the study compared the incidence of central nervous system (CNS) adverse events (AEs) by Week 8 in patients who received doravirine 100 mg plus TDF\/FTC (n=108) versus","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:49+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/","name":"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2014-11-03T05:00:00+00:00","dateModified":"2023-03-22T04:04:49+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141103005159r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-doravirine-mk-1439-in-treatment-naive-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"439e1539-4d8d-45d7-b1a2-1c9c38ba72df","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Data-from-48-Week-Phase-2b-Study-of-Investigational-HIV-Therapy-Doravirine-MK-1439-in-Treatment-Naive-Patients-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744904\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744904"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}